This study is currently not recruiting participants.

Treatment Plan for Brincidofovir (CMX001 BCV) in a Named Patient with Adenovirus Hepatitis Infection

Investigating an Investigational Medication for Adenovirus Hepatitis Infection

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

This protocol is for the use of brincidofovir in a single adult patient with adenovirus hepatitis infection.

Detailed description of study

This protocol is for the use of brincidofovir in a single adult patient with adenovirus hepatitis infection.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Adenovirus Hepatitis Infection
  • Age: 100 years or below
  • Gender: All

This study investigates the use of an investigational medication for treating adenovirus hepatitis infection in adults. Adenovirus hepatitis is a liver infection caused by the adenovirus, which can lead to liver inflammation and damage.

Participants in this study will receive the investigational medication, which aims to target the adenovirus causing the liver infection. The study will monitor the effects and safety of the medication during the treatment period.

  • Who can participate: A single adult diagnosed with adenovirus hepatitis infection is eligible to participate.
  • Study details: A single participant will receive the investigational medication to assess its effects on adenovirus hepatitis infection. The study will involve regular monitoring to evaluate the medication's safety and effectiveness.
Updated on 19 Feb 2024. Study ID: 1706765791

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team